Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.71037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Burcu Uzunoglu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Selim Cöremen Cystic Fibrosis Center, Pendik Education and Training Hospital, Marmara University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Although modulator therapies have proven effective in cystic fibrosis (CF) access is limited due to reimbursement issues in Turkey. We aimed to examine anxiety and depression levels of people with CF (pwCF) and their caregivers according to their access to modulator treatment.
Methods
Participants genetically eligible for elexacaftor/tezacaftor/ivacaftor (ETI) were divided into Group 1 (access via court decision, not yet on treatment) and Group 2 (unable to access due to reimbursement issues). Genetically ineligible participants formed Group 3. All pwCF and parents of those under 18 were screened for depression by the Patient Health Questionnaire‐9 (PHQ‐9) and for anxiety by the Generalized Anxiety Disorder‐7 (GAD‐7). Surveys for Group 1 patients were conducted just before starting ETI. Binary logistic regression analysis was performed to evaluate the effects of independent variables on anxiety and depression in pwCF and their primary caregivers.
Results
A total of 389 pwCF and 285 caregivers were included. Group 3 (ineligible) had the highest depression rate (72.9%, n = 35), while Group 1 (pre‐ETI) had the lowest (50.0%, n = 35). Median PHQ‐9 scores were significantly lower in Group 1 ( p < 0.006). Anxiety rates were higher in Groups 2 and 3 compared to Group 1 ( p = 0.011 and p = 0.003, respectively). Access to ETI reduced the odds of anxiety by 67.7% ( p = 0.029). Caregiver GAD‐7 scores showed a weak negative correlation with pwCF age (r = −0.117).
Conclusion
Limited access to modulator therapies is associated with higher depression and anxiety symptoms among pwCF. Addressing these barriers is critical to improving their well‐being.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Selim Cöremen Cystic Fibrosis Center, Pendik Education and Training Hospital, Marmara University, Istanbul, Turkey.
- Division of Pediatric Pulmonology, School of Medicine, Marmara University, Istanbul, Turkey.
- Nutrition and Dietetics, Pendik Education and Training Hospital, Marmara University, Istanbul, Turkey.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Uzunoglu, B., Selcuk Balci, M., Kalyoncu, M., Karabulut, S., Metin Cakar, N., Yildiz, C. A., Tastan, G., Kocaman, D., Ergenekon, A. P., Gökdemir, Y., Erdem Eralp, E., Karakoc, F., & Karadag, B. (2025). Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71037
Vancouver
Uzunoglu B, Selcuk Balci M, Kalyoncu M, Karabulut S, Metin Cakar N, Yildiz CA, et al. Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71037
BibTeX
@article{Uzunoglu2025,
author = {Uzunoglu, Burcu and Selcuk Balci, Merve and Kalyoncu, Mine and Karabulut, Seyda and Metin Cakar, Neval and Yildiz, Ceren Ayca and Tastan, Gamze and Kocaman, Damla and Ergenekon, Almala Pinar and Gökdemir, Yasemin and Erdem Eralp, Ela and Karakoc, Fazilet and Karadag, Bülent},
title = {Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.71037}
}
EUVIMED